IFNA17 and hereditary clear cell renal cell carcinoma: Bevacizumab was the first angiogenesis inhibitor to be approved for use in first-line therapy of renal cell carcinoma, after the pivotal AVOREN trial proved a 37% reduction in the risk of disease progression (hazard ratio = 0.63; p = 0.0001) with the addition of Bevacizumab to INF-α therapy compared with INF-α alone [103,105,106], which, however, did not translate into an overall survival benefit.